Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral Proteins

키워드

참고문헌 (109)

1. Beyrer C, "HIV drug resistance-an emerging threat to epidemic control", N. Engl. J. Med, 377, pp.1605~1607 (2017)
2. Kormuth KA, "Emerging antiviral resistance", Nat. Microbiol, 5, pp.4~5 (2020)
3. Zhang H, "Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis", Nat. Commun, 14, pp.7457~ (2023)
4. Zou G, "Current state and challenges in respiratory syncytial virus drug discovery and development", Antiviral Res, 221, pp.105791~ (2024)
5. Wei Y, "Recent advances in enterovirus A71 infection and antiviral agents", Lab. Invest, 104, pp.100298~ (2023)
6. Mahajan S, "Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens", Bioorg. Med. Chem, 46, pp.116356~ (2021)
7. Xiao T, "HIV-1 entry and membrane fusion inhibitors", Viruses, 13, pp.735~ (2021)
8. Segal-Maurer S, "Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection", N. Engl. J. Med, 386, pp.1793~1803 (2022)
9. Kang JX, "Recent advances on dual inhibitors targeting HIV reverse transcriptase associated polymerase and ribonuclease H", Eur. J. Med. Chem, 250, pp.115196~ (2023)
10. Boby ML, "Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors", Science, 382, pp.eabo7201~ (2023)
11. Lee C, "CRISPR", Cas9-based antiviral strategy : current status and the potential challenge, 2019, pp.24, 1349~
12. Nguyen H, "Efficient inhibition of HIV using CRISPR", Cas13d nuclease system, 2021, pp.13, 1850~
13. Leal ES, "Unveiling tetrahydroquinolines as promising BVDV entry inhibitors : targeting the envelope protein", Virology, 590, pp.109968~ (2024)
14. Bai Y, "Antivirals targeting the surface glycoproteins of influenza virus : mechanisms of action and resistance", Viruses, 13, pp.624~ (2021)
15. Zhang Q, "Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors", Exp. Opin. Pharmacother, 22, pp.715~728 (2021)
16. Kadam RU, "Structural basis of influenza virus fusion inhibition by the antiviral drug arbidol", Proc. Natl. Acad. Sci. USA, 114, pp.206~214 (2017)
17. Badani H, "Mechanism and action of flufirvitide, a peptide inhibitor of influenza virus infection", Biophys. J, 100, pp.216a~ (2011)
18. Han X, "Synthesis and in vitro anti-influenza virus evaluation of novel sialic acid(C-5 and C-9)-pentacyclic triterpene derivatives", Molecules, 22, pp.1018~ (2017)
19. Tsuji M, "Synthesis and anti-influenza virus evaluation of triterpene-sialic acid conjugates", Bioorg. Med. Chem, 26, pp.17~24 (2018)
20. Sautto GA, "Hemagglutinin consensus-based prophylactic approaches to overcome influenza virus diversity", Vet. Italiana, 55, pp.195~201 (2019)
21. Wu NC, "Influenza hemagglutinin structures and antibody recognition", Cold Spring Harb. Perspect. Med, 10, pp.a038778~ (2020)
22. McAuley JL, "Influenza virus neuraminidase structure and functions", Front. Microbiol, 10, pp.39~ (2019)
23. Gong J, "Structure and functions of influenza virus neuraminidase", Curr. Med. Chem, 14, pp.113~122 (2007)
24. van der Vries E, "Influenza virus resistance to antiviral therapy", Adv. Pharmacol, 67, pp.217~246 (2013)
25. Han J, "Influenza virus : small molecule therapeutics and mechanisms of antiviral resistance", Curr. Med. Chem, 25, pp.5115~5127 (2018)
26. Lampejo T, "Influenza and antiviral resistance : an overview", Eur. J. Clin. Microbiol. Infect. Dis, 39, pp.1201~1208 (2020)
27. Yang H, "Structural biology of SARS-CoV-2 and implications for therapeutic development", Nat. Rev. Microbiol, 19, pp.685~700 (2021)
28. Cai Y, "Distinct conformational states of SARS-CoV-2 spike protein", Science, 369, pp.1586~1592 (2020)
29. Wang Q, "Structural and functional basis of SARS-CoV-2 entry by using human ACE2", Cell, 181, pp.894~904 (2020)
30. Yan R, "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", Science, 367, pp.1444~1448 (2020)
31. Vankadari N, "Arbidol : a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein", Int. J. Antimicrob. Agents, 56, pp.105998~ (2020)
32. Padhi AK, "Unraveling the mechanism of arbidol binding and inhibition of SARSCoV-2 : insights from atomistic simulations", Eur. J. Pharmacol, 894, pp.173836~ (2021)
33. Barnes CO, "Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies", Cell, 182, pp.828~842 (2020)
34. Shi R, "A human neutralizing antibody targets the receptor-binding site of SARSCoV-2", Nature, 584, pp.120~124 (2020)
35. Yuan M, "Structural basis of a shared antibody response to SARS-CoV-2", Science, 369, pp.1119~1123 (2020)
36. Chan DC, "Core structure of gp41 from the HIV envelope glycoprotein", Cell, 89, pp.263~273 (1997)
37. Weissenhorn W, "Atomic structure of the ectodomain from HIV-1 gp41", Nature, 387, pp.426~430 (1997)
38. Lai YT, "Small molecule HIV-1 attachment inhibitors : discovery, mode of action and structural basis of inhibition", Viruses, 13, pp.843~ (2021)
39. Dove A, "New class of HIV drugs shows promise", Nat. Med, 7, pp.1265~ (2001)
40. Kilby JM, "The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide(T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults", AIDS Res. Human Retroviruses, 18, pp.685~693 (2002)
41. Aiken C, "The HIV-1 capsid and reverse transcription", Retrovirology, 18, pp.29~ (2021)
42. Dvory-Sobol H, "Lenacapavir : a first-in-class HIV-1 capsid inhibitor", Curr. Opin. HIV AIDS, 17, pp.15~21 (2022)
43. Thenin-Houssier S, "HIV-1 capsid inhibitors as antiretroviral agents", Curr. HIV Res, 14, pp.270~282 (2016)
44. Kuduk SD, "Oxadiazepinone HBV capsid assembly modulators", Bioorg. Med. Chem. Lett, 52, pp.128353~ (2021)
45. Kim W, "Discovery of novel pyrimidine-based capsid assembly modulators as potent anti-HBV agents", J. Med. Chem, 64, pp.5500~5518 (2021)
46. Toyama M, "Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly", Virus Res, 271, pp.197677~ (2019)
47. Qiu Z, "Design and synthesis of orally bioavailable 4-Methyl heteroaryldihydropyrimidine based hepatitis B virus(HBV)capsid inhibitors", J. Med. Chem, 59, pp.7651~7666 (2016)
48. Giacchello I, "Insights into RNA-dependent RNA polymerase inhibitors as antiinfluenza virus agents", Curr. Med. Chem, 28, pp.1068~1090 (2021)
49. Massari S, "Inhibition of influenza virus polymerase by interfering with its protein-protein interactions", ACS Infect. Dis, 7, pp.1332~1350 (2021)
50. Yuan S, "Inhibitors of influenza A virus polymerase", ACS Infect. Dis, 4, pp.218~223 (2018)
51. Furuta Y, "Favipiravir(T-705), a novel viral RNA polymerase inhibitor", Antiviral Res, 100, pp.446~454 (2013)
52. Furuta Y, "Favipiravir(T-705), a broad spectrum inhibitor of viral RNA polymerase", Proc. Japan Acad. Ser. B Phys. Biol. Sci, 93, pp.449~463 (2017)
53. Shiraki K, "Favipiravir, an anti-influenza drug against life-threatening RNA virus infections", Pharmacol. Ther, 209, pp.107512~ (2020)
54. Mifsud EJ, "Antivirals targeting the polymerase complex of influenza viruses", Antiviral Res, 169, pp.104545~ (2019)
55. Patel MC, "Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir", Antiviral Res, 188, pp.105035~ (2021)
56. Takashita E, "Influenza polymerase inhibitors : mechanisms of action and resistance", Cold Spring Harb. Perspect. Med, 11, pp.a038687~ (2021)
57. Gao Y, "Structure of the RNA-dependent RNA polymerase from COVID-19 virus", Science, 368, pp.779~782 (2020)
58. Chen J, "Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex", Cell, 182, pp.1560~1573 (2020)
59. Wang Q, "Structural basis for RNA replication by the SARS-CoV-2 polymerase", Cell, 182, pp.417~428 (2020)
60. Brüssow H, "Clinical trials with antiviral drugs against COVID-19 : some progress and many shattered hopes", Environ. Microbiol, 23, pp.6364~6376 (2021)
61. Peng F, "Recent advances on drugs and vaccines for COVID-19", Inquiry, 58, pp.469580211055630~ (2021)
62. Wu J, "Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex", Cell Rep, 37, pp.109882~ (2021)
63. Yin W, "Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin", Nat. Struct. Mol. Biol, 28, pp.319~325 (2021)
64. De Clercq E, "1984-discovery of the first anti-HIV drug, suramin", Viruses, 13, pp.1646~ (2021)
65. Havens JP, "Clinical pharmacokinetics and pharmacodynamics of etravirine : an updated review", Clin. Pharmacokinet, 59, pp.137~154 (2020)
66. Schrijvers R, "Etravirine for the treatment of HIV", AIDS, 2013, pp.14, 1087~1096
67. Soriano V, "Advances in hepatitis B therapeutics", Ther. Adv. Infect. Dis, 7, pp.2049936120965027~ (2020)
68. Gao J, "Research progress on the direct antiviral drugs for hepatitis C virus", Biosci. Ttrends, 11, pp.41~45 (2017)
69. Zeuzem S, "Treatment options in hepatitis C", Deutsches Arzteblatt International, 114, pp.11~21 (2017)
70. furan-3-ol, a key subunit of HIV-1 protease inhibitor drug, darunavir, "J. Organic Chem", 2021, 1216~1222
71. Llibre JM, "From TMC114 to darunavir : five years of data on efficacy", AIDS Rev, 15, pp.112~121 (2013)
72. Paton NI, "Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV", N. Eng. J. Med, 385, pp.330~341 (2021)
73. Sarkar A, "Repurposing an antiviral drug against SARS-CoV-2 main protease", Angew. Chem. Int. Ed Engl, 60, pp.23492~23494 (2021)
74. Dai W, "Structure-based design of antiviral drug candidates targeting the SARSCoV-2 main protease", Science, 368, pp.1331~1335 (2020)
75. Jin Z, "Structure of M(pro)from SARS-CoV-2 and discovery of its inhibitors", Nature, 582, pp.289~293 (2020)
76. Zhao Y, "Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332", Protein Cell, 13, pp.689~693 (2022)
77. Zhang L, "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors", Science, 368, pp.409~412 (2020)
78. Gunther S, "X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease", Science, 372, pp.642~646 (2021)
79. Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", N. Engl. J. Med, 382, pp.1787~1799 (2020)
80. Gao X, "Crystal structure of SARS-CoV-2 papain-like protease", Acta Pharm. Sin. B, 11, pp.237~245 (2021)
81. Osipiuk J, "Structure of papain-like protease from SARS-CoV-2and its complexes with non-covalent inhibitors", Nat. Commun, 12, pp.743~ (2021)
82. Rut W, "Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design", Sci. Adv, 6, pp.eabd4596~ (2020)
83. Keating GM, "Elbasvir", grazoprevir : first global approval, 2016, pp.76, 617~624
84. Wang SJ, "Elbasvir and grazoprevir for the treatment of hepatitis C", Exp. Rev. Anti-Infect. Ther, 19, pp.1071~1081 (2021)
85. Świerczyńska M, "Antiviral drugs in influenza", Int. J. Environ. Res. Public Health, 19, pp.3018~ (2022)
86. Dong G, "Adamantane-resistant influenza a viruses in the world(1902-2013) : frequency and distribution of M2 gene mutations", PLoS One, 10, pp.e0119115~ (2015)
87. Engel DA, "The influenza virus NS1 protein as a therapeutic target", Antiviral Res, 99, pp.409~416 (2013)
88. Cho EJ, "Identification of influenza virus inhibitors targeting NS1A utilizing fluorescence polarization-based high-throughput assay", J. Biomol. Screening, 17, pp.448~459 (2012)
89. Gao Y, "Inhibition of hepatitis C virus infection by DNA aptamer against NS2protein", PLoS One, 9, pp.e90333~ (2014)
90. Alexopoulou A, "New approaches to the treatment of chronic Hepatitis B", J. Clin. Med, 9, pp.3187~ (2020)
91. Hussein M, "A CRISPR-cas cure for HIV", AIDS, 2023, pp.24, 1563~
92. Kurt Yilmaz N, "Introduction : drug resistance", Chem. Rev, 121, pp.3235~3237 (2021)
93. Du S, "Target-based drug design strategies to overcome resistance to antiviral agents : opportunities and challenges", Drug Resist. Updat, 73, pp.101053~ (2024)
94. Ouyang Y, "Virus-like plasmonic nanoprobes for quick analysis of antiviral efficacy and mutation-induced drug resistance", Anal. Chem, 95, pp.5009~5017 (2023)
95. Ahmadian E, "Monitoring of drug resistance towards reducing the toxicity of pharmaceutical compounds : past, present and future", J. Pharm. Biomed. Anal, 186, pp.113265~ (2020)
96. Van Poelvoorde LAE, "Next-generation sequencing : an eye-opener for the surveillance of antiviral resistance in influenza", Trends Biotechnol, 38, pp.360~367 (2020)
97. He Y, "Antibody inhibition of influenza A virus assembly and release", J. Virol, 98, pp.e0139823~ (2024)
98. Matthys A, "Promises and challenges of single-domain antibodies to control influenza", Antiviral Res, 222, pp.105807~ (2024)
99. Liu Y, "N(6)-methyladenosine RNA modification-mediated cellular metabolism rewiring inhibits viral replication", Science, 365, pp.1171~1176 (2019)
100. Li P, "RNA 2'-O-methyltransferase fibrillarin facilitates virus entry into macrophages through inhibiting type I interferon response", Front. Immunol, 13, pp.793582~793595 (2022)
101. Rani M, "Natural flavonoid pectolinarin computationally targeted as a promising drug candidate against SARS-CoV-2", Curr. Res. Struct. Biol, 7, pp.100120~ (2024)
102. Fang PL, "Lindenane disesquiterpenoids with anti-HIV-1 activity from Chloranthus japonicus", J. Nat. Prod, 74, pp.1408~1413 (2011)
103. Luo L, "Analysis on herbal medicines utilized for treatment of COVID-19", Acta Pharm. Sin. B, 10, pp.1192~1204 (2020)
104. Luo L, "Natural products for infectious microbes and diseases : an overview of sources, compounds, and chemical diversities", Sci. China Life Sci, 65, pp.1123~1145 (2022)
105. Ahmed-Belkacem R, "5'-cap RNA", SAM mimetic conjugates as bisubstrate inhibitors of viral RNA cap 2'-O-methyltransferases, 2023, pp.143, 107035~
106. Ge R, "Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection", SLAS Discov, 27, pp.79~85 (2022)
107. Haider Z, "In-silico pharmacophoric and molecular dockingbased drug discovery against the Main Protease(Mpro)of SARS-CoV-2, a causative agent COVID-19", Pak. J. Pharm. Sci, 33, pp.2697~2705 (2020)
108. Liu J, "A high-throughput drug screening strategy against coronaviruses", Int. J. Infect. Dis, 103, pp.300~304 (2021)
109. Zhao Y, "High-throughput screening identifies established drugs as SARS-CoV-2PLpro inhibitors", Protein Cell, 12, pp.877~888 (2021)

관련 논문AI추천